---
tags: [medicine, davidson, hematology, wm, waldenstrom-macroglobulinaemia, lymphoplasmacytic-lymphoma, fcps, mrcp]
davidson_chapter: Chapter 25: Haematology and Transfusion Medicine
status: full-fcps-mrcp-note
priority: high
exam_relevance: "FCPS: Essential | MRCP: Core | IgM paraprotein, MYD88 L265P, CXCR4 mutations, hyperviscosity syndrome, BTK inhibitors (ibrutinib/zanubrutinib), rituximab-based regimens"
see_also: "[[Multiple Myeloma]], [[MGUS]], [[AL Amyloidosis]], [[Hyperviscosity Syndrome]], [[BTK Inhibitors]]"
created: 2025-06-16
modified: 2025-06-16
---

# Waldenström Macroglobulinaemia (WM)

> [!info] **Davidson Ch 25 Alignment**: Haematological Malignancies → Plasma Cell Disorders → Waldenström Macroglobulinaemia
> **FCPS/MRCP Focus**: IgM paraprotein, MYD88 L265P (+ CXCR4), hyperviscosity syndrome, BTK inhibitors (ibrutinib/zanubrutinib), rituximab-based regimens, IPSSWM prognosis

---

## 🎯 Learning Objectives

- [ ] Define WM: **Lymphoplasmacytic lymphoma** with **IgM paraprotein** and **bone marrow infiltration** by lymphoplasmacytic cells
- [ ] Diagnose: **IgM paraprotein**, **MYD88 L265P mutation** (>90%), **CXCR4 mutations** (~30-40%), **BM lymphoplasmacytic infiltration**
- [ ] Recognise **Hyperviscosity Syndrome**: IgM >40-50 g/L → visual changes, neurological symptoms, bleeding → **Emergency Plasmapheresis**
- [ ] Apply **IPSSWM** for prognosis: Age >65, Hb ≤11.5, Plt ≤100, β2M >3, IgM >70
- [ ] Manage **Asymptomatic**: Observation ("Watch & Wait")
- [ ] Manage **Symptomatic**: **BTK Inhibitors** (Ibrutinib/Zanubrutinib) ± Rituximab; **Rituximab-based chemo** (BR, DRC) if BTKi contraindicated
- [ ] Avoid **Rituximab monotherapy** in high IgM (flare risk)
- [ ] Monitor: IgM, FLC, CBC, β2M, IgM viscosity

---

## 📖 Definition & Diagnostic Criteria

| Criterion | Requirement |
|-----------|-------------|
| **IgM Paraprotein** | **Any level** (typically >30 g/L) |
| **Bone Marrow** | **Lymphoplasmacytic infiltration** (≥10% usually); **CD20+, CD19+, CD23-, CD5-, CD10-, Cyclin D1-** |
| **MYD88 Mutation** | **L265P >90%** (diagnostic hallmark) |
| **CXCR4 Mutation** | **~30-40%** (WHIM-like; associated with lower IgM, higher BM involvement, BTKi resistance) |

> [!tip] **FCPS/MRCP**: **WM = IgM Paraprotein + Lymphoplasmacytic Lymphoma + MYD88 L265P**. **CXCR4 mut = BTKi resistance**. **Hyperviscosity = Emergency Plasmapheresis**. **BTKi (Ibrutinib/Zanubrutinib) = Standard**.

---

## ⚙️ Pathophysiology

```mermaid
flowchart TD
    A[MYD88 L265P Mutation] --> B[Constitutive NF-κB Activation]
    B --> C[Survival & Proliferation of Lymphoplasmacytic Cells]
    C --> D[IgM Paraprotein Production]
    D --> E1[Hyperviscosity (IgM Pentamer)]
    D --> E2[Cryoglobulinaemia (Type I)]
    D --> E3[Cold Agglutinin Activity]
    D --> E4[Neuropathy (Anti-MAG)]
    C --> F[CXCR4 Mutation] --> G[Enhanced Homing to BM] --> H[Higher BM Involvement, Lower IgM]
    G --> I[**BTK Inhibitor Resistance**]
```

---

## 🔬 Diagnostic Workup

```mermaid
flowchart TD
    A[IgM Paraprotein + Lymphadenopathy/Splenomegaly/B-symptoms] --> B[**SPEP + Immunofixation: IgM κ/λ**]
    B --> C[**sFLC (κ/λ ratio)**]
    C --> D[**Bone Marrow Aspirate + Biopsy**]
    D --> E[**Flow: CD20+, CD19+, CD23-, CD5-, CD10-, Cyclin D1-**]
    E --> F[**MYD88 L265P PCR/NGS** (>90%)]
    F --> G[**CXCR4 NGS** (~30-40%)]
    G --> H[**CBC, β2M, IgM, Viscosity, Cryoglobulins, Anti-MAG**]
    H --> I[**IPSSWM Prognostic Score**]
    I --> J[**Imaging: CT Chest/Abd/Pelvis** (lymphadenopathy/splenomegaly)]
```

### Key Investigations

| Test | WM Finding |
|------|------------|
| **SPEP + Immunofixation** | **IgM κ/λ Paraprotein** (often >30 g/L) |
| **sFLC** | **κ/λ ratio abnormal** (involved light chain) |
| **BM Biopsy** | **Lymphoplasmacytic infiltration** (interstitial/nodular) |
| **Flow Cytometry** | **CD20+, CD19+, FMC7+, CD23-, CD5-, CD10-, Cyclin D1-** |
| **MYD88 L265P** | **>90% positive** (diagnostic) |
| **CXCR4** | **~30-40% mutated** (WHIM-like) |
| **Viscosity** | **Correlates with IgM level** (hyperviscosity if >40-50 g/L) |
| **Cryoglobulins** | **Type I (IgM)** – cold-induced precipitation |
| **Anti-MAG Antibodies** | **Peripheral neuropathy** (demyelinating) |

---

## 🩺 Clinical Features

| Manifestation | Details |
|---------------|---------|
| **Hyperviscosity Syndrome** | **IgM >40-50 g/L**: Visual disturbances (blurring, retinopathy), Neurological (headache, dizziness, stroke), Mucosal bleeding, **Emergency Plasmapheresis** |
| **Anaemia** | BM infiltration, haemodilution (high IgM), autoimmune (AIHA) |
| **Lymphadenopathy/Splenomegaly** | Common |
| **Peripheral Neuropathy** | **Anti-MAG** (demyelinating, distal symmetric); **Cryoglobulinaemia** |
| **Cryoglobulinaemia** | **Type I (IgM)**: Cold-induced precipitation → Raynaud's, purpura, glomerulonephritis |
| **Bing-Neel Syndrome** | **CNS infiltration** by WM cells → headache, cognitive, cranial nerve palsies |
| **Autoimmune Phenomena** | AIHA, ITP, Cold Agglutinin Disease |

---

## 📊 Prognostic Scoring – IPSSWM

| Variable | Points |
|----------|--------|
| **Age >65** | 1 |
| **Hb ≤11.5 g/dL** | 1 |
| **Platelets ≤100** | 1 |
| **β2-Microglobulin >3 mg/L** | 1 |
| **IgM >70 g/L** | 1 |

| Risk Group | Score | Median OS |
|------------|-------|-----------|
| **Low** | 0-1 | ~14-15 years |
| **Intermediate** | 2 | ~8-10 years |
| **High** | ≥3 | ~5-6 years |

---

## 💊 Management

### Asymptomatic (Smouldering WM) – **Observe**
- **No treatment** until symptomatic
- **Monitor q3-6mo**: CBC, IgM, β2M, viscosity, renal function

### Symptomatic – Treatment Indications
- **Hyperviscosity** (IgM >40-50 g/L)
- **Anaemia** (Hb <10 g/dL) due to BM infiltration
- **Symptomatic lymphadenopathy/splenomegaly**
- **Constitutional symptoms** (B-symptoms)
- **Neuropathy** (Anti-MAG, Bing-Neel)
- **Cryoglobulinaemia** with end-organ damage
- **Thrombocytopenia** (Plt <100) due to BM infiltration

### First-Line Treatment Options

| Regimen | Components | Key Points |
|---------|------------|------------|
| **Ibrutinib** | 420 mg daily (continuous) | **First-line standard** (iNNOVATE, ASPEN); **AFib, bleeding, HTN** |
| **Zanubrutinib** | 160 mg BD (continuous) | **Preferred over Ibrutinib** (ASPEN: less AFib, less discontinuation) |
| **Ibrutinib + Rituximab** | Ibrutinib 420mg + Rituximab 375mg/m² ×4 | **iNNOVATE**: Superior PFS vs Rituximab alone |
| **BR (Bendamustine + Rituximab)** | Benda 90mg/m² d1,2 + Rituximab 375mg/m² d1 q28d ×6 | **If BTKi contraindicated**; **Avoid if prior BTKi** (cross-resistance) |
| **DRC (Dex, Rituximab, Cyclophosphamide)** | Alternative to BR | Similar efficacy |

> [!warning] **Avoid Rituximab MONOTHERAPY if IgM >40 g/L** (risk of **IgM flare** → worsening hyperviscosity). **Give BTKi first or combine with Rituximab**.

### Hyperviscosity Syndrome – **Emergency**
- **Plasmapheresis** (1-1.5 plasma volumes daily until IgM <30 g/L / symptoms resolve)
- **Then start BTKi** (Ibrutinib/Zanubrutinib) for disease control

### Relapsed/Refractory WM

| Setting | Options |
|---------|---------|
| **BTKi-naïve** | **Zanubrutinib** (preferred) / Ibrutinib |
| **BTKi-relapsed** | **Venetoclax** (BCL-2 high in WM), **PI3K inhibitors** (Idelalisib, Duvelisib), **Proteasome inhibitors** (Bortezomib, Carfilzomib), **CAR-T** (investigational), **Clinical trials** |

---

## 🔄 Differential Diagnosis

| Condition | Distinguishing Features |
|-----------|------------------------|
| **IgM MGUS** | **IgM <30 g/L**, **BMPC <10%**, **No symptoms** – observe |
| **Multiple Myeloma** | **Non-IgM** (IgG/IgA/LC), **CRAB/SLiM**, **BMPC ≥10%** |
| **MCL** | **Cyclin D1+, t(11;14)**, **SOX11+**, **IgM rare** |
| **FL/MZL** | **CD10+/BCL2+ (FL)**, **CD5-/CD23- (MZL)**, **No IgM paraprotein** |
| **CLL/SLL** | **CD5+, CD23+, CD20 dim, sIg dim**, **No IgM paraprotein** |
| **Bing-Neel Syndrome** | **CNS symptoms + WM**; **CSF flow + WM cells**, **MRI leptomeningeal enhancement** |

---

## 💡 FCPS/MRCP High-Yield Summary

| Topic | Key Point |
|-------|-----------|
| **Diagnosis** | **IgM Paraprotein + Lymphoplasmacytic BM + MYD88 L265P (>90%)** |
| **CXCR4 Mutation** | **~30-40%**; **WHIM-like** → **Lower IgM, Higher BM, BTKi Resistance** |
| **Hyperviscosity** | **IgM >40-50 g/L** → Visual, Neuro, Bleeding → **Emergency Plasmapheresis** |
| **Anti-MAG Neuropathy** | **Demyelinating**, IgM anti-MAG antibodies; treat WM |
| **First-line** | **BTK Inhibitor: Zanubrutinib** (preferred) / Ibrutinib ± Rituximab |
| **BTKi Resistance** | **CXCR4 Mutation** → Consider Venetoclax/PI3Ki/Proteasome Inhibitors |
| **Rituximab Flare** | **Avoid if IgM >40 g/L** (hyperviscosity risk); Combine with BTKi |
| **IPSSWM** | Age>65, Hb≤11.5, Plt≤100, β2M>3, IgM>70 |
| **Bing-Neel** | **CNS WM** – CSF flow, MRI, treat with BTKi/CNS-penetrant chemo |
| **Cryoglobulinaemia** | **Type I IgM** – Raynaud's, purpura, GN; Treat WM |

---

## ❓ Viva Questions

1. **What is the diagnostic hallmark mutation in Waldenström Macroglobulinaemia?**
   - **MYD88 L265P** (>90% of cases)

2. **What is the significance of CXCR4 mutation in WM?**
   - **WHIM-like phenotype**: Lower IgM, higher BM involvement, **BTK inhibitor resistance**

3. **What is hyperviscosity syndrome and how is it managed?**
   - **IgM >40-50 g/L**: Visual, neurological, bleeding → **Emergency Plasmapheresis** followed by BTKi

4. **What is the first-line treatment for symptomatic WM?**
   - **BTK Inhibitor: Zanubrutinib (preferred) / Ibrutinib** ± Rituximab

5. **Why should Rituximab monotherapy be avoided in high IgM?**
   - **IgM Flare** (transient rise in IgM → worsening hyperviscosity); **Use BTKi first or combine**

6. **What is the IPSSWM prognostic score?**
   - Age >65, Hb ≤11.5, Plt ≤100, β2M >3, IgM >70 (0-1 Low, 2 Int, ≥3 High)

7. **How does Bing-Neel Syndrome present and how is it diagnosed?**
   - **CNS infiltration**: Headache, cognitive, cranial nerves → **CSF Flow + WM cells + MRI leptomeningeal enhancement**

8. **What is the role of Anti-MAG antibodies in WM?**
   - **Demyelinating peripheral neuropathy**; treat underlying WM (BTKi)

9. **How does CXCR4 mutation affect BTK inhibitor response?**
   - **BTKi Resistance** (CXCR4 mut → enhanced BM homing, impaired drug penetration); Consider Venetoclax/PI3Ki

10. **Differentiate WM from IgM MGUS and Multiple Myeloma.**
    - **IgM MGUS**: IgM <30g/L, BMPC <10%, asymptomatic; **WM**: IgM any, BM infiltration + symptoms; **MM**: Non-IgM, CRAB/SLiM, BMPC ≥10%

---

## 🧠 Confusions & Mnemonics

| Confusion | Clarification |
|-----------|---------------|
| **WM vs IgM MGUS** | **WM = Symptomatic + BM Infiltration**; **IgM MGUS = Asymptomatic, IgM <30, BMPC <10%** |
| **WM vs MCL** | **WM = MYD88 L265P, IgM**; **MCL = Cyclin D1+, t(11;14), SOX11+** |
| **Rituximab Flare** | **IgM >40 g/L + Rituximab → IgM Rise → Hyperviscosity** |
| **CXCR4 Mutation** | **WHIM-like** (Warts, Hypogammaglobulinaemia, Infections, Myelokathexis) → **BTKi Resistance** |
| **Bing-Neel** | **CNS WM** – CSF Flow + MRI leptomeningeal |

| Mnemonic | Meaning |
|----------|---------|
| **"WM = IgM + MYD88 L265P"** | Diagnostic hallmarks |
| **"CXCR4 = BTKi Resistance"** | Mutation significance |
| **"Hyperviscosity = Plasmapheresis NOW"** | Emergency management |
| **"Rituximab Flare = IgM >40 = Avoid Mono"** | Rituximab caution |
| **"IPSSWM = Age>65, Hb↓, Plt↓, β2M↑, IgM↑"** | Prognostic score |
| **"Bing-Neel = CNS WM = CSF Flow + MRI"** | CNS involvement |
| **"Zanubrutinib > Ibrutinib (Less AFib)"** | BTKi choice |

---

## 🗺️ Mind Map

```mermaid
mindmap
  root((Waldenström Macroglobulinaemia))
    Diagnosis
      IgM Paraprotein
      Lymphoplasmacytic BM
      MYD88 L265P (>90%)
      CXCR4 Mut (~30-40%)
    Clinical
      Hyperviscosity (IgM>40-50)
      Anaemia, Lymphadenopathy
      Anti-MAG Neuropathy
      Cryoglobulinaemia (Type I)
      Bing-Neel (CNS)
    Prognosis
      IPSSWM: Age>65, Hb≤11.5, Plt≤100, β2M>3, IgM>70
    Treatment
      Asymptomatic: Observe
      Symptomatic: BTKi (Zanubrutinib > Ibrutinib) ± Rituximab
      NO Rituximab Mono if IgM>40
      Hyperviscosity: Plasmapheresis → BTKi
    Resistance
      CXCR4 Mut → BTKi Resistant
      Venetoclax / PI3Ki / Proteasome Inhibitors
    Differential
      IgM MGUS (Asymptomatic)
      Myeloma (Non-IgM, CRAB)
      MCL (Cyclin D1+)
      CLL (CD5+, CD23+)
```

---

## 📋 One-Page Revision Card

| **WALDENSTRÖM MACROGLOBULINAEMIA – FCPS/MRCP REVISION CARD** |
|---------------------------------------------------------------|
| **Diagnosis**: **IgM Paraprotein + Lymphoplasmacytic BM + MYD88 L265P (>90%)** |
| **CXCR4 Mut**: ~30-40% → **Lower IgM, Higher BM, BTKi Resistance** |
| **Hyperviscosity**: **IgM >40-50 g/L** → **Emergency Plasmapheresis** |
| **Anti-MAG Neuropathy**: Demyelinating, Treat WM |
| **1st Line**: **Zanubrutinib** (preferred) / **Ibrutinib** ± Rituximab |
| **Rituximab Flare**: **IgM >40 g/L → Avoid Mono** |
| **IPSSWM**: Age>65, Hb≤11.5, Plt≤100, β2M>3, IgM>70 |
| **Bing-Neel**: CNS WM → CSF Flow + WM cells + MRI |
| **Cryoglobulinaemia**: Type I IgM → Raynaud's, GN |
| **IgM MGUS**: <30g/L, BMPC<10%, Asymptomatic |

---

## 📅 Spaced Repetition Tracker

| Review | Date | Score (1-5) | Next Review |
|--------|------|-------------|-------------|
| Day 1 | 2025-06-16 | | 2025-06-17 |
| Day 3 | | | |
| Day 7 | | | |
| Day 15 | | | |
| Day 30 | | | |

---

## 🎯 Must Know / Should Know / Nice to Know

| Level | Content |
|-------|---------|
| **Must Know** | IgM + MYD88 L265P + lymphoplasmacytic BM, CXCR4 mutation = BTKi resistance, hyperviscosity = plasmapheresis emergency, zanubrutinib preferred over ibrutinib, Rituximab flare if IgM>40, IPSSWM, Bing-Neel CNS, Anti-MAG neuropathy |
| **Should Know** | MYD88 signaling (NF-κB), CXCR4 WHIM-like phenotype, zanubrutinib vs ibrutinib trial data (ASPEN), bing-neel CSF/MRI, cryoglobulinaemia management, rituximab flare kinetics, PI3Ki (idelalisib) in BTKi-relapsed, venetoclax in WM, CAR-T in WM, familial WM, ibrutinib discontinuation syndrome |
| **Nice to Know** | Detailed CXCR4 mutation types (nonsense vs frameshift), BTKi pharmacokinetics in WM, rituximab flare mechanism (FcγR-mediated plasmablast activation), Bing-Neel treatment protocols (ibrutinib + high-dose cytarabine), novel agents (pirtobrutinib, nemtabrutinib), WM in paediatrics, bone marrow microenvironment |

---

## ✅ Self-Test Scorecard

| Section | Score (0-10) | Notes |
|---------|--------------|-------|
| Diagnostic Criteria & MYD88/CXCR4 | | |
| Clinical Features & Hyperviscosity | | |
| IPSSWM Prognostication | | |
| BTK Inhibitor Therapy | | |
| Rituximab Flare & Hyperviscosity | | |
| Bing-Neel & Cryoglobulinaemia | | |
| Viva Questions | | |

---

## 🔗 Local Navigation

- **Previous**: [[Amyloidosis (AL)]]
- **Next**: [[Hairy Cell Leukaemia]]
- **Section Hub**: [[Haematological Malignancies]]
- **MOC**: [[Hematology MOC]]
- **Template**: [[../Templates/Hematology Topic Template]]

---

*Generated for FCPS/MRCP exam preparation. Based on Davidson Medicine 24th Ed Chapter 25.*
---

> Auto-generated study sections for "Hematology" — Ch 24: Haematology & Transfusion Medicine.

## Flashcards (33 generated)

- Q: What is the definition of Hematology?
  A: [!info] Davidson Ch 25 Alignment: Haematological Malignancies → Plasma Cell Disorders → Waldenström Macroglobulinaemia
- Q: What is IgM Paraprotein of Hematology?
  A: Any level (typically >30 g/L)
- Q: What is Bone Marrow of Hematology?
  A: Lymphoplasmacytic infiltration (≥10% usually); CD20+, CD19+, CD23-, CD5-, CD10-, Cyclin D1-
- Q: What is MYD88 Mutation of Hematology?
  A: L265P >90% (diagnostic hallmark)
- Q: What is CXCR4 Mutation of Hematology?
  A: ~30-40% (WHIM-like; associated with lower IgM, higher BM involvement, BTKi resistance)
- Q: What is SPEP + Immunofixation of Hematology?
  A: IgM κ/λ Paraprotein (often >30 g/L)
- Q: What is sFLC of Hematology?
  A: κ/λ ratio abnormal (involved light chain)
- Q: What is BM Biopsy of Hematology?
  A: Lymphoplasmacytic infiltration (interstitial/nodular)
- Q: What is Flow Cytometry of Hematology?
  A: CD20+, CD19+, FMC7+, CD23-, CD5-, CD10-, Cyclin D1-
- Q: What is MYD88 L265P of Hematology?
  A: >90% positive (diagnostic)
- Q: What is CXCR4 of Hematology?
  A: ~30-40% mutated (WHIM-like)
- Q: What is Viscosity of Hematology?
  A: Correlates with IgM level (hyperviscosity if >40-50 g/L)
- Q: What is Cryoglobulins of Hematology?
  A: Type I (IgM) – cold-induced precipitation
- Q: What is Anti-MAG Antibodies of Hematology?
  A: Peripheral neuropathy (demyelinating)
- Q: What is SPEP + Immunofixation of Hematology?
  A: IgM κ/λ Paraprotein (often >30 g/L)
- Q: What is sFLC of Hematology?
  A: κ/λ ratio abnormal (involved light chain)
- Q: What is BM Biopsy of Hematology?
  A: Lymphoplasmacytic infiltration (interstitial/nodular)
- Q: What is Flow Cytometry of Hematology?
  A: CD20+, CD19+, FMC7+, CD23-, CD5-, CD10-, Cyclin D1-
- Q: What is MYD88 L265P of Hematology?
  A: >90% positive (diagnostic)
- Q: What is CXCR4 of Hematology?
  A: ~30-40% mutated (WHIM-like)
- Q: What is Viscosity of Hematology?
  A: Correlates with IgM level (hyperviscosity if >40-50 g/L)
- Q: What is Cryoglobulins of Hematology?
  A: Type I (IgM) – cold-induced precipitation
- Q: What is Anti-MAG Antibodies of Hematology?
  A: Peripheral neuropathy (demyelinating)
- Q: What is the investigation of choice for Hematology?
  A: IgM Paraprotein + Lymphoplasmacytic BM + MYD88 L265P (>90%)
- Q: What is CXCR4 Mutation of Hematology?
  A: ~30-40%; WHIM-like → Lower IgM, Higher BM, BTKi Resistance
- Q: What is Hyperviscosity of Hematology?
  A: IgM >40-50 g/L → Visual, Neuro, Bleeding → Emergency Plasmapheresis
- Q: What is Anti-MAG Neuropathy of Hematology?
  A: Demyelinating, IgM anti-MAG antibodies; treat WM
- Q: What is the first-line treatment for Hematology?
  A: BTK Inhibitor: Zanubrutinib (preferred) / Ibrutinib ± Rituximab
- Q: What is BTKi Resistance of Hematology?
  A: CXCR4 Mutation → Consider Venetoclax/PI3Ki/Proteasome Inhibitors
- Q: What is Rituximab Flare of Hematology?
  A: Avoid if IgM >40 g/L (hyperviscosity risk); Combine with BTKi
- Q: What is IPSSWM of Hematology?
  A: Age>65, Hb≤11.5, Plt≤100, β2M>3, IgM>70
- Q: What is Bing-Neel of Hematology?
  A: CNS WM – CSF flow, MRI, treat with BTKi/CNS-penetrant chemo
- Q: What is Cryoglobulinaemia of Hematology?
  A: Type I IgM – Raynaud's, purpura, GN; Treat WM

## MCQs (1 generated)

1. **Which of the following best describes Hematology?**
   A. **[!info] Davidson Ch 25 Alignment: Haematological Malignancies → Plasma Cell Disorders → Waldenström Macroglobulinaemia**
   B. An unrelated condition not matching the clinical picture of Hematology
   C. A complication seen late in the disease course of Hematology
   D. A condition that mimics Hematology but has a different underlying cause

## SBA Questions (1 generated)

1. A patient with suspected Hematology presents with: IgM Paraprotein — Any level (typically >30 g/L); Bone Marrow — Lymphoplasmacytic infiltration (≥10% usually); CD20+, CD19+, CD23-, CD5-, CD10-, Cyclin D1-; MYD88 Mutation — L265P >90% (diagnostic hallmark). What is the most likely diagnosis?
   A. **Hematology**
   B. A condition that mimics Hematology but is not the same entity
   C. A complication of Hematology rather than the primary diagnosis
   D. An unrelated condition in the same clinical category as Hematology

